Member Info for L2analyst

Dream boat, are you saying a company held by.nick mather has increased holding to 15%? That would be a very significant news

Any trade over 13.7 is buy some trades shows sell.but actually are buys

Oil price will only go higher, people need to come to their sense , some producers will simply stop if they cant make profit

I wonder if we get another asset sell before the new ceo arrives, highly likely imo

Looks to me seller is cleared, should break out now, l2 looking fantastic

Buys coming thick n fast

Remember they said they will dispose over a billion dollars assets , more news due, shorts will.get toast

120k buy

I think we are about to move up now

Just added 10k at full price

I have to say that is a very good news

Yesterday last 3 trades were at 13.65p !!!!

Fantastic close

This got to breakout

Partnership with gsk would be nice for the flu-v

The way I see is that our treatment will be given to people who have covid as a first defence against the virus, as it works, I think imminent approval soon

"Companies don’t usually announce the appointment of advisors. The press picked it up and we made a statement which you can review here: https://www.redcloudfs.com/rcwebinar-solg/   

 

Happy to confirm that we appointed Citi to help us with a couple of strategic matters related to M&A and financing. They were appointed after we ran a beauty parade including several banks, and we might even add further advisors to our efforts to increase shareholder value via a competitive bidding process."

 

Its already successful

"Strengthened balance sheet for potential partnering discussions with regards to the COVID-19, 

From placin rns

"Early data from this double-blind, placebo-controlled trial have demonstrated that the antiviral responses in the lung (assessed using sputum biomarkers) are similar to those observed in the asthma trial, where we saw clinical benefit in lung function.

 

Use of proceeds

 

COVID-19 clinical trial activity

£7m

Manufacture of SNG001 drug product and other supply chain considerations

£4m

Strengthened balance sheet for potential partnering discussions with regards to the COVID-19, future pandemic preparedness, and the COPD opportunity, working capital and fees

£3m